Clinical trial
CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer
NCT00043394 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00043394 |
|---|---|
| Title | CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer |
| Official title | A Phase I/II Open Label, Multi-Center, Dose-Escalation Study Of Subcutaneous CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Breast |
| Intervention type | Drug |
| Interventions | 0.04 mg/kg CpG 7909, Herceptin®, 0.08 mg/kg CpG 7909, 0.12 mg/kg CpG 7909, 0.16 mg/kg CpG 7909 |
| Enrollment | 16 |
| Start date | Sep 1, 2002 |
| Primary completion | Oct 1, 2003 |
| Completion | Oct 1, 2003 |
| First posted | Aug 12, 2002 |
| Last update posted | Mar 12, 2009 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: